Genital Warts (Condyloma Acuminatum) Market

Request Methodology

Genital Warts Market Snapshot (2023 to 2033)

The global genital warts (condyloma acuminatum) market is expected to reach a valuation of US$ 1.87 Billion in 2023 and is projected to increase to US$ 3 Billion by 2033, with a CAGR of 4.84%. The dynamics of the genital warts market are expected to change in the coming years owing to the expected launch of emerging drugs. Key players, such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others, are developing drugs for genital warts. Moreover, successful, and well-communicated vaccination programs have increased public knowledge of vaccines and their advantages, resulting in greater vaccine uptake. In addition, increased vaccination coverage has been linked to a lower occurrence of genital warts.

Factors such as the rise in the prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections and growth in the male population are further anticipated to boost the overall growth of the genital warts treatment market within the forecast period. Furthermore, the genital warts market is fuelled by the increasing availability of therapies developed for self-target applications.

Additionally, the quadrivalent HPV vaccination has been proven to prevent genital warts and cervical cancer. The effectiveness of Imiquimod topical administration may be boosted by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a stronger therapeutic response than vaccination.

Moreover, the therapeutics landscape and genital warts market expects more patient-applied modalities that provide the simplicity of application, safety, and the benefit of self-administration. The rising incidence of various malignancies underlines the disparity in exposure and risk factors between genital wart patients and the general population. The paucity of effective data and alternate treatment regimens makes it challenging for doctors to deliver the appropriate treatment when initial treatments fail. Thus, all the factors mentioned above act as an obstruction to the growth of the genital warts market.

Lack of awareness about the diagnosis & treatment of such diseases and the high cost of treatment are some factors restricting growth. There is a high unmet need for targeted drugs with enhanced clinical profiles at low costs and convenient administration schedules. However, increasing Research and Development expenditure on oncologic diseases offers a promising future for the market in the foreseeable future.

Data Points	Key Statistics
Expected Market Value (2023)	US$ 1.87 Billion
Anticipated Forecast Value (2033)	US$ 3 Billion
Projected Growth Rate (2023 to 2033)	CAGR 4.84%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Genital Warts Demand Analysis vs. Forecast 2023 to 2033

The global industry for Genital Warts was valued at around US$ 1 billion in the historical period while exhibiting a CAGR of 2.02%. The pandemic negatively affected the market but noteworthy growth was witnessed during the post-pandemic period.

Moreover, the increasing availability of therapies developed for self-target applications and the use of physical destruction treatment therapies such as Cryotherapy and other chemical treatments in treating Genital warts have augmented market growth. Considering these factors, FMI has projected the market to grow at a CAGR of 4.84%, while reaching a valuation of US$ 3 Billion by end of the forecast period.

Which are Some Prominent Drivers of the Genital Warts Market?

Emerging therapies to propel the Market Growth

The genital warts market is fuelled by the increasing availability of therapies developed for self-target applications. Additionally, the quadrivalent HPV vaccination has been proven to prevent genital warts and cervical cancer. The effectiveness of Imiquimod topical administration may be boosted by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a stronger therapeutic response than vaccination

Additionally, the growing focus of pharmaceutical manufacturers on the development of therapeutics that can be administered by the patient themselves and growing levels of availability for therapeutics designed for target applications/indications of HPV globally will also augment the genital warts treatment market in the forecast period.

Also, increasing research and development for therapies and treatments are to further extend suitable prospects for the growth of the genital warts treatment market in the near future.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Unawareness and complications regarding vaccines and therapies hinder the growth

The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that restrict genital warts market growth. In addition, current treatments for genital warts are mostly ablative or topical administrations of Imiquimod cream and Sinecatechins (Polyphenon E) ointment, but major issues with low patient compliance and high recurrence rates have been noted due to systemic adverse effects.

Furthermore, due to the length of time required for successful treatment and high recurrence rates, the present genital warts treatment paradigm, which includes manual excision of warts, is far from optimum. Patients with genital warts are more prone to develop HPV-related cancers, particularly anogenital malignancies, thus hampering the growth of this market.

The complications linked with the utilization of vaccines and therapeutics for the HPV virus might hamper the market’s growth which can be one of the challenging factors within the forecast period. Existing treatment procedures are often painful or invasive, and can have undesirable outcomes such as scarring or dyspigmentation that often requires repeat visits. This results in a decrease in the diagnostic rate, which in turn, is likely to restrain the genital warts therapeutics market.

Furthermore, there are no specific treatments available for genital warts. The most commonly used treatments are cauterization and freezing. On the other hand, topical skin medications that are generally prescribed for the treatment of warts are commonly prescribed for skin conditions and skin cancers as well. These aforementioned factors will hold back the market expansion.

Region-Wise Insights

North America is expected to dominate the Genitals Warts Market

In terms of revenue, North America dominated the genital warts market with a market share of 40% followed by Europe. the market is growing with a CAGR of 4.2% in the forecast period of 2023 to 2033 and is expected to attain a valuation of US$ 1.5 Billion by 2033.

Well-established healthcare infrastructure, rising prevalence of STDs and genital warts cases, early adoption of advanced products, and presence of key players are major factors that are anticipated to drive the market in the region. Moreover, focus on research & development by leading players is expected to boost the market.

APAC to be the Fastest Growing Market for Genital warts

Asia Pacific region is projected to observe the fastest growth throughout the forecast period. Swift economic development, improvements in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely factors that contribute to regional growth.

Emerging economies of China, India, South Korea, and others are anticipated to observe strong growth in the coming years. The market is projected to grow with a CAGR of 4.5% in the forecast period and is expected to reach US$ 900 Million by 2033.

Category wise Insights

Hospital Pharmacies be the dominant Channel of Distribution for Selling Genital Warts Treatment Drugs

Hospital pharmacies are expected to capture the largest share among distribution channels by 2033. Hospital pharmacies preserve the stock of products related to HPV-associated disorders like Genital Warts, mainly for outpatients and inpatients.

The segment will be driven by growing consumer awareness and increased investments in healthcare infrastructure across developing and underdeveloped economies.

Chemical Treatment of Genital Warts to be Most Preferred

The chemical treatment segment is expected to dominate the global genital warts therapeutics market, in terms of revenue by 2033. The use of Imiquimod (Aldara, Zyclara), Podophyllin and podofilox (Condylox), Trichloroacetic acid, and Sinecatechins (Veregen) are expected to fuel the market growth of genital warts during the forecast period.

Start-ups in Genital Warts Market

Founded in 2009, ‘Cassiopeia’ is an Italian, clinical-stage pharma company focused on dermatology. Their initial focus is on the topical treatment of acne, androgenic alopecia, and genital warts. They have 4 drug candidates in clinical development: Winlevi, for acne- in Phase III trials, Breezula for androgenic alopecia - in Phase II trials, CB - for acne in phase II, and CB - for HPV in Phase I. The company was originally called Cosmo Dermatos and changed its name to Cassiopea in Apr.2015. It received funding from Dievini
Swift is a Melbourne, Australia-based, Developer of a device for the treatment of HPV warts. The device Swift delivers microwave energy directly into the affected tissue which releases immune system signaling molecules to fight human papillomavirus which causes warts.
Founded in 2014, PathoVax is a US-based start-up that is focused on the development of universal Human Papillomavirus (HPV) vaccine to provide prophylaxis against all HPV-related cancers and diseases. The company claims that its pilot vaccine, RGVax, promises to provide protection against all 15 oncogenic HPVs and many others that cause various warts. It received a total funding of US$ 9.75 Million.

Market Competition

Key players in the Genital Warts market are Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Medicis Pharmaceuticals, Aresus Pharma, AbbVie, Sanofi S.A., AbbVie Inc, Perrigo Company PLC, Glenmark Pharmaceuticals. Some key developments in this market are:

In 2019, GenieMD, a global provider of telemedicine services, launched its telemedicine app iVisit which would allow patients to be diagnosed and treated for genital warts via a virtual visit with a physician.
In August 2018, Oceanside Pharmaceuticals, a company which provides pharmaceutical services, launched an authorized generic version of Bausch Health’s Zyclara (imiquimod) 3.75% cream pump. Zyclara (imiquimod) 3.75% is indicated for the topical treatment of external genital and perianal warts/condyloma acuminate (EGW) in patients of age 12 years or older.
In June 2020, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., had declared the US FDA approval for GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of HPV-related cervical, vaginal, vulvar, anal, oropharyngeal, and other head and neck cancers. The FDA approval received would result in addressing the unmet clinical needs of the patients, and increased distribution of the vaccine in hospitals and cancer research institutes, for the rise in product sales.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 1.87 Billion
Market Value in 2033	US$ 3 Billion
Growth Rate	CAGR of 4.84% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ Billion and CAGR from 2023-2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Treatment Distribution Channel Region
Regions Covered	North America Latin America Europe South Asia & Pacific East Asia Middle East & Africa (MEA)
Key Countries Profiled	The US Canada Brazil Mexico Mexico Germany The UK France Spain Italy India Malaysia Singapore Thailand China Japan South Korea Australia New Zealand GCC countries South Africa Israel
Key Companies Profiled	Verrica Pharmaceuticals Tamir Biotechnology Novan Inc. Medicis Pharmaceuticals Aresus Pharma AbbVie Inc. Sanofi S.A. Perrigo Company PLC Glenmark Pharmaceuticals
Customization	Available Upon Request

Key Segments Profiled in the Genital Warts Market Industry survey

Genital Warts Market by Treatment:

Chemical Treatment
Ablative Treatment
Preventive Treatment
Other Treatments

Genital Warts Market by Distribution Channel:

Hospital Pharmacies
Retail pharmacies
Online Pharmacies

Genital Warts Market by Region:

North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East & Africa (MEA)

Frequently Asked Questions

What is the anticipated growth of the Genital Warts market until 2033?

FMI projects the global genital warts market to expand at a 4.84% value CAGR by 2033.

What is the estimated market value of the Genital Warts market expected in 2033?

The global genital warts market is expected to garner a market value of US$ 3 Billion by 2033.

Which region is forecast to be the most lucrative for genital warts market growth?

FMI has projected North America to be one of the most profitable regions for the Genital Warts market.

Which region is expected to grow fastest during the forecast period?

APAC region is expected to grow fastest during the forecast period.

Table of Content

1. Executive Summary | Genital Warts (Condyloma Acuminatum) Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

5.3.1. Chemical Treatment

5.3.2. Ablative Treatment

5.3.3. Preventive Treatment

5.3.4. Other Treatments

5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

6.3.1. Hospital Pharmacies

6.3.2. Retail Pharmacies

6.3.3. Online Pharmacies

6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. South Asia & Pacific

7.3.5. East Asia

7.3.6. Middle East & Africa (MEA)

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. The US

8.2.1.2. Canada

8.2.2. By Treatment

8.2.3. By Distribution Channel

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Treatment

8.3.3. By Distribution Channel

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Treatment

9.2.3. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment

9.3.3. By Distribution Channel

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. The UK

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Treatment

10.2.3. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment

10.3.3. By Distribution Channel

10.4. Key Takeaways

11. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. India

11.2.1.2. Malaysia

11.2.1.3. Singapore

11.2.1.4. Thailand

11.2.1.5. Australia

11.2.1.6. New Zealand

11.2.1.7. Rest of South Asia & Pacific

11.2.2. By Treatment

11.2.3. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment

11.3.3. By Distribution Channel

11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.2. By Treatment

12.2.3. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Treatment

12.3.3. By Distribution Channel

12.4. Key Takeaways

13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. GCC Countries

13.2.1.2. South Africa

13.2.1.3. Israel

13.2.1.4. Rest of MEA

13.2.2. By Treatment

13.2.3. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Treatment

13.3.3. By Distribution Channel

13.4. Key Takeaways

14. Key Countries Market Analysis

14.1. U.S.

14.1.1. Pricing Analysis

14.1.2. Market Share Analysis, 2022

14.1.2.1. By Treatment

14.1.2.2. By Distribution Channel

14.2. Canada

14.2.1. Pricing Analysis

14.2.2. Market Share Analysis, 2022

14.2.2.1. By Treatment

14.2.2.2. By Distribution Channel

14.3. Brazil

14.3.1. Pricing Analysis

14.3.2. Market Share Analysis, 2022

14.3.2.1. By Treatment

14.3.2.2. By Distribution Channel

14.4. Mexico

14.4.1. Pricing Analysis

14.4.2. Market Share Analysis, 2022

14.4.2.1. By Treatment

14.4.2.2. By Distribution Channel

14.5. Germany

14.5.1. Pricing Analysis

14.5.2. Market Share Analysis, 2022

14.5.2.1. By Treatment

14.5.2.2. By Distribution Channel

14.6. The UK

14.6.1. Pricing Analysis

14.6.2. Market Share Analysis, 2022

14.6.2.1. By Treatment

14.6.2.2. By Distribution Channel

14.7. France

14.7.1. Pricing Analysis

14.7.2. Market Share Analysis, 2022

14.7.2.1. By Treatment

14.7.2.2. By Distribution Channel

14.8. Spain

14.8.1. Pricing Analysis

14.8.2. Market Share Analysis, 2022

14.8.2.1. By Treatment

14.8.2.2. By Distribution Channel

14.9. Italy

14.9.1. Pricing Analysis

14.9.2. Market Share Analysis, 2022

14.9.2.1. By Treatment

14.9.2.2. By Distribution Channel

14.10. India

14.10.1. Pricing Analysis

14.10.2. Market Share Analysis, 2022

14.10.2.1. By Treatment

14.10.2.2. By Distribution Channel

14.11. Malaysia

14.11.1. Pricing Analysis

14.11.2. Market Share Analysis, 2022

14.11.2.1. By Treatment

14.11.2.2. By Distribution Channel

14.12. Singapore

14.12.1. Pricing Analysis

14.12.2. Market Share Analysis, 2022

14.12.2.1. By Treatment

14.12.2.2. By Distribution Channel

14.13. Thailand

14.13.1. Pricing Analysis

14.13.2. Market Share Analysis, 2022

14.13.2.1. By Treatment

14.13.2.2. By Distribution Channel

14.14. Australia

14.14.1. Pricing Analysis

14.14.2. Market Share Analysis, 2022

14.14.2.1. By Treatment

14.14.2.2. By Distribution Channel

14.15. New Zealand

14.15.1. Pricing Analysis

14.15.2. Market Share Analysis, 2022

14.15.2.1. By Treatment

14.15.2.2. By Distribution Channel

14.16. China

14.16.1. Pricing Analysis

14.16.2. Market Share Analysis, 2022

14.16.2.1. By Treatment

14.16.2.2. By Distribution Channel

14.17. Japan

14.17.1. Pricing Analysis

14.17.2. Market Share Analysis, 2022

14.17.2.1. By Treatment

14.17.2.2. By Distribution Channel

14.18. South Korea

14.18.1. Pricing Analysis

14.18.2. Market Share Analysis, 2022

14.18.2.1. By Treatment

14.18.2.2. By Distribution Channel

14.19. GCC Countries

14.19.1. Pricing Analysis

14.19.2. Market Share Analysis, 2022

14.19.2.1. By Treatment

14.19.2.2. By Distribution Channel

14.20. South Africa

14.20.1. Pricing Analysis

14.20.2. Market Share Analysis, 2022

14.20.2.1. By Treatment

14.20.2.2. By Distribution Channel

14.21. Israel

14.21.1. Pricing Analysis

14.21.2. Market Share Analysis, 2022

14.21.2.1. By Treatment

14.21.2.2. By Distribution Channel

15. Market Structure Analysis

15.1. Competition Dashboard

15.2. Competition Benchmarking

15.3. Market Share Analysis of Top Players

15.3.1. By Regional

15.3.2. By Treatment

15.3.3. By Distribution Channel

16. Competition Analysis

16.1. Competition Deep Dive

16.1.1. Verrica Pharmaceuticals

16.1.1.1. Overview

16.1.1.2. Product Portfolio

16.1.1.3. Profitability by Market Segments

16.1.1.4. Sales Footprint

16.1.1.5. Strategy Overview

16.1.1.5.1. Marketing Strategy

16.1.2. Tamir Biotechnology

16.1.2.1. Overview

16.1.2.2. Product Portfolio

16.1.2.3. Profitability by Market Segments

16.1.2.4. Sales Footprint

16.1.2.5. Strategy Overview

16.1.2.5.1. Marketing Strategy

16.1.3. Novan Inc.

16.1.3.1. Overview

16.1.3.2. Product Portfolio

16.1.3.3. Profitability by Market Segments

16.1.3.4. Sales Footprint

16.1.3.5. Strategy Overview

16.1.3.5.1. Marketing Strategy

16.1.4. Medicis Pharmaceuticals

16.1.4.1. Overview

16.1.4.2. Product Portfolio

16.1.4.3. Profitability by Market Segments

16.1.4.4. Sales Footprint

16.1.4.5. Strategy Overview

16.1.4.5.1. Marketing Strategy

16.1.5. Aresus Pharma

16.1.5.1. Overview

16.1.5.2. Product Portfolio

16.1.5.3. Profitability by Market Segments

16.1.5.4. Sales Footprint

16.1.5.5. Strategy Overview

16.1.5.5.1. Marketing Strategy

16.1.6. AbbVie

16.1.6.1. Overview

16.1.6.2. Product Portfolio

16.1.6.3. Profitability by Market Segments

16.1.6.4. Sales Footprint

16.1.6.5. Strategy Overview

16.1.6.5.1. Marketing Strategy

16.1.7. Sanofi S.A.

16.1.7.1. Overview

16.1.7.2. Product Portfolio

16.1.7.3. Profitability by Market Segments

16.1.7.4. Sales Footprint

16.1.7.5. Strategy Overview

16.1.7.5.1. Marketing Strategy

16.1.8. AbbVie Inc.

16.1.8.1. Overview

16.1.8.2. Product Portfolio

16.1.8.3. Profitability by Market Segments

16.1.8.4. Sales Footprint

16.1.8.5. Strategy Overview

16.1.8.5.1. Marketing Strategy

16.1.9. Perrigo Company PLC

16.1.9.1. Overview

16.1.9.2. Product Portfolio

16.1.9.3. Profitability by Market Segments

16.1.9.4. Sales Footprint

16.1.9.5. Strategy Overview

16.1.9.5.1. Marketing Strategy

16.1.10. Glenmark Pharmaceuticals

16.1.10.1. Overview

16.1.10.2. Product Portfolio

16.1.10.3. Profitability by Market Segments

16.1.10.4. Sales Footprint

16.1.10.5. Strategy Overview

16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2023 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2023 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2023 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2023 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2023 to 2033

Table 13: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 14: South Asia & Pacific Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 15: South Asia & Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2023 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2023 to 2033

Table 19: MEA Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 20: MEA Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 21: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2023 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2023 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2023 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2023 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2023 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2023 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia & Pacific Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: South Asia & Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: South Asia & Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 65: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia & Pacific Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 68: South Asia & Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 69: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Treatment , 2023 to 2033

Figure 70: South Asia & Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2023 to 2033

Figure 71: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: South Asia & Pacific Market Attractiveness by Treatment, 2023 to 2033

Figure 74: South Asia & Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: South Asia & Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2023 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 92: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 93: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: MEA Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 95: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: MEA Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 98: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 99: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 100: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2023 to 2033

Figure 101: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 102: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 103: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 104: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 105: MEA Market Attractiveness by Country, 2023 to 2033

December 2022

REP-GB-16211

290 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -